Efforts to improve education on biosimilars are a start, but payer policies must catch up to ensure real change.
Mike Gladstone
Advertisement
Articles by Mike Gladstone
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sponsored: The Teva Biosimilars Trend Report
2
Topical Ruxolitinib Cream Rapidly Repigments Vitiligo Lesions, Study Finds
3
FDA Accepts NDA for Investigational Maintenance Asthma Treatment
4
The 6-Year Cure Threshold: Redefining Cure for Colon Cancer Survivors
5
